Targeting BTK and Bcl-2 for B-Cell Malignancies: Where Are We Moving Toward? episode artwork

EPISODE · Jan 17, 2024 · 21 MIN

Targeting BTK and Bcl-2 for B-Cell Malignancies: Where Are We Moving Toward?

from Keeping Current CME

Expert insights on the latest clinical findings on targeting Bruton tyrosine kinase (BTK) and B-cell lymphoma 2 (Bcl-2) to treat B-cell malignancies. Credit available for this activity expires: 1/12/25 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/999658?ecd=bdc_podcast_libsyn_mscpedu

Episode metadata supplied by the publisher feed · Published Jan 17, 2024

Embed this episode

NOW PLAYING

Targeting BTK and Bcl-2 for B-Cell Malignancies: Where Are We Moving Toward?

0:00 21:28

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Keeping Current CME?

This episode is 21 minutes long.

When was this Keeping Current CME episode published?

This episode was published on January 17, 2024.

Can I download this Keeping Current CME episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!